Neo-Concept International Group Holdings Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NCI research report →
Price Chart
About the company
Neo-Concept International Group Holdings Limited, established in 2021 and headquartered in Kwun Tong, Hong Kong, operates as a comprehensive provider of apparel solutions. This subsidiary of Neo-concept (BVI) Limited offers a wide spectrum of services throughout the clothing supply chain. These services include analyzing market trends, designing and developing products, procuring raw materials, overseeing production and quality assurance, and managing logistics.
- CEO
- Jiang Pengfei
- IPO
- 2024
- Employees
- 24
- HQ
- Kwun Tong, HK
Get TickerSpark's AI analysis on NCI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.19M
- P/E
- -0.69
- PEG
- 0.01
- P/S
- 0.14
- P/B
- 0.07
- EV/EBITDA
- -2205.86
- Div Yield
- 0.00%
- Gross Margin
- 34.24%
- Op Margin
- -3.82%
- Net Margin
- -4.15%
- ROE
- -13.89%
- ROIC
- -6.02%
Latest fiscal year · YoY change
- Revenue
- $137.25M-41.8%
- Gross Profit
- $50.69M+2.5%
- Op Income
- $1.80M
- Net Income
- $331.68K-95.9%
- EPS
- $5.20-79.7%
- OCF Growth
- +4891.3%
- FCF Growth
- +192.7%
- 52W High
- $883.84
- 52W Low
- $2.00
- 50D MA
- $27.13
- 200D MA
- $122.20
- Beta
- -2.87
- RSI (14)
- 23
- Avg Volume
- 137.79K
No earnings-call transcripts are available for NCI yet.
- Free Float
- 90.0%
- Shares Outstanding
- 1.04M
- Float Shares
- 938.85K
of shares held by institutions
171 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Teachers Advisors, LLC | 123.70K | ▲ 3.32K |
| Tiaa Cref Investment Management LLC | 111.71K | ▼ 4.29K |
| Oppenheimerfunds, Inc. | 23.52K | ▲ 3.37K |
| Bbt Capital Management, LLC | 10.90K | ▲ 10.90K |
| Alpha Quant Advisors, LLC | 261 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 25, 26 | Jiang Pengfei | other | 140,000 |
| Aug 10, 26 | Peter Chun Ming Pang | other | 0 |
| May 29, 26 | Siu Eva Yuk Yin | other | 0 |
| Mar 18, 26 | Wong Chun Kwok | other | 0 |
| Mar 18, 26 | Lau Patrick Kwok Fai | other | 0 |
| Mar 18, 26 | Singer Mark Gary | other | 0 |
| Mar 18, 26 | Jiang Pengfei | other | 0 |
| Mar 18, 26 | Siu Eva Yuk Yin | other | 0 |
| Mar 18, 26 | Siu Eva Yuk Yin | other | 0 |
| Mar 18, 26 | Tang Billy Chun Fai | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NCI coverage
Recent articles, reports, and earnings notes.
No research on NCI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NCI report →Purple Biotech's IM1240, a CAPTN-3-Capped Tri-Specific T- and NK-Cell Engager Targeting 5T4, Shows Robust Tumor Killing in Immunotherapy-Resistant Cancer Models in Plenary Oral Presentation at EORTC-NCI-AACR Symposium
globenewswire.com · Nov 20
Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium
globenewswire.com · Nov 18
Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
globenewswire.com · Nov 18
Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
globenewswire.com · Nov 4
Neo-Concept International Announces Share Consolidation
globenewswire.com · Nov 2
Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
globenewswire.com · Oct 29
Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
globenewswire.com · Oct 27
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
globenewswire.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.